It was only yesterday that the World Health Organization (WHO) declared that the Zika virus is an international public health emergency. Sanofi Pasteur, the vaccine division of Sanofi, announced today that it has launched a vaccine development effort.
Blood analysis in patients with inflammatory rheumatic diseases such as psoriatic arthritis indicates that biologic medications do not reduce the efficacy of anti-pneumococcal polysaccharide vaccine, and that patients with such conditions may not need to be vaccinated more frequently than others.
The research shows conclusively that the influenza vaccine is effective at protecting people from sickness. But unfortunately, not every person is eligible to receive the potentially life-saving vaccination.
It’s not too late to get a flu vaccine, and now there’s a new one to consider. The first seasonal flu vaccine containing an adjuvant, Fluad, received accelerated approval from the US Food and Drug Administration (FDA) for adults age 65 and older.
The FDA has approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease.
While many people get their flu vaccine on a yearly basis there are some who are still hesitant while others simply refuse. New modes of delivery and new guidelines aim to help answer some lingering questions patients may have.